Revance Therapeutics, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Mark J. Foley
- Full Time Employees
- 597
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1222 Demonbreun Street Nashville TN United States of America 37203
- IPO Date
- Feb 6, 2014
- CIK
- 0001479290
- Website
- revance.com
- Similar Companies
- Business
- Revance Therapeutics, Inc. (RVNC) is a biotechnology company that develops, manufactures, and commercializes neuromodulators and related products for aesthetic and therapeutic indications. The company offers DAXXIFY (daxibotulinumtoxinA-lanm) for injection to treat glabellar lines and cervical dystonia; the RHA Collection of hyaluronic acid dermal fillers distributed in partnership with Teoxane SA; a portfolio of skincare products including the number-one selling mineral sunscreen brand and skin barrier strengthening formulas; the number-one microneedling device in the US; a platelet rich plasma system; and therapeutics advancing treatments for movement disorders. Revance operates globally with products available in the United States and through partnerships such as Viatris for a biosimilar to onabotulinumtoxinA and Fosun for DAXXIFY commercialization in China. Founded in 1999 and headquartered in Nashville, Tennessee, Revance completed its acquisition by Crown Laboratories in February 2025, uniting the companies under the REVANCE brand to expand its aesthetics, skincare, and therapeutics portfolio; the firm also reached a milestone of distributing one million vials of DAXXIFY in the US and launched the Teoxane RHA Collection with Mepivacaine anesthetic.
REVANCE ALERT: Bragar Eagel & Squire, P.C. is Investigating Revance Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Revance Announces Blue Lizard® Australian Sunscreen Times Square Takeover to Celebrate National Sunscreen Day
REVANCE ALERT: Bragar Eagel & Squire, P.C. is Investigating Revance Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Class Action Filed Against Revance Therapeutics, Inc. (RVNC) Seeking Recovery for Investors - Contact Levi & Korsinsky
Levi & Korsinsky Notifies Revance Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - RVNC
RVNC DEADLINE TODAY: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Revance Therapeutics, Inc. Investors to Secure Counsel Before Important March 4 Deadline in Securities Class Action – RVNC
Contact Levi & Korsinsky by March 4, 2025 Deadline to Join Class Action Against Revance Therapeutics, Inc. (RVNC)
Contact Levi & Korsinsky by March 4, 2025 Deadline to Join Class Action Against Revance Therapeutics, Inc. (RVNC)
Revance Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Revance Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 4, 2025 - RVNC
FINAL REMINDER RVNC DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Revance Therapeutics, Inc. Investors to Participate in the Class Action Lawsuit
Investors who lost money on Revance Therapeutics, Inc.(RVNC) should contact Levi & Korsinsky about pending Class Action - RVNC
Investors who lost money on Revance Therapeutics, Inc.(RVNC) should contact Levi & Korsinsky about pending Class Action - RVNC
March 4, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against RVNC
RVNC DEADLINE TOMORROW: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Revance Therapeutics, Inc. Investors to Secure Counsel Before Important March 4 Deadline in Securities Class Action – RVNC
Class Action Filed Against Revance Therapeutics, Inc. (RVNC) - March 4, 2025 Deadline to Join - Contact Levi & Korsinsky
Deadline Soon: Revance Therapeutics, Inc. (RVNC) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
Revance Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – RVNC
Levi & Korsinsky Notifies Shareholders of Revance Therapeutics, Inc. (RVNC) of a Class Action Lawsuit and an Upcoming Deadline
Revance Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Revance Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 4, 2025 - RVNC
Shareholders that lost money on Revance Therapeutics, Inc.(RVNC) should contact The Gross Law Firm about pending Class Action - RVNC